CD1d-antibody fusion proteins target iNKT cells to the tumor and trigger long-term therapeutic responses

Despite the well-established antitumor activity of CD1d-restricted invariant natural killer T lymphocytes (iNKT), their use for cancer therapy has remained challenging. This appears to be due to their strong but short-lived activation followed by long-term anergy after a single administration of the...

Descripción completa

Detalles Bibliográficos
Autores principales: Corgnac, Stéphanie, Perret, Rachel, Derré, Laurent, Zhang, Lianjun, Stirnemann, Kathrin, Zauderer, Maurice, Speiser, Daniel E., Mach, Jean-Pierre, Romero, Pedro, Donda, Alena
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer-Verlag 2012
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3624007/
https://www.ncbi.nlm.nih.gov/pubmed/23242316
http://dx.doi.org/10.1007/s00262-012-1381-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3624007/
https://www.ncbi.nlm.nih.gov/pubmed/23242316
http://dx.doi.org/10.1007/s00262-012-1381-7

Ejemplares similares